218 related articles for article (PubMed ID: 15667961)
1. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
2. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Krauss DJ; Karrison T; Martinez AA; Morton G; Yan D; Bruner DW; Movsas B; Elshaikh M; Citrin D; Hershatter B; Michalski JM; Efstathiou JA; Currey A; Kavadi VS; Cury FL; Lock M; Raben A; Seaward SA; El-Gayed A; Rodgers JP; Sandler HM
J Clin Oncol; 2023 Jun; 41(17):3203-3216. PubMed ID: 37104748
[TBL] [Abstract][Full Text] [Related]
3. Conditional Risks of Biochemical Failure and Prostate Cancer-Specific Death in Patients Undergoing External Beam Radiotherapy: A Secondary Analysis of 2 Randomized Clinical Trials.
Alexander GS; Krc RF; Assif JW; Sun K; Molitoris JK; Tran P; Rana Z; Bentzen SM; Mishra MV
JAMA Netw Open; 2023 Sep; 6(9):e2335069. PubMed ID: 37751207
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.
Zhu Z; Zhang J; Liu Y; Chen M; Guo P; Li K
Br J Cancer; 2014 May; 110(10):2396-404. PubMed ID: 24736585
[TBL] [Abstract][Full Text] [Related]
6. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
7. Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy.
Takano S; Tomita N; Niwa M; Torii A; Takaoka T; Kita N; Uchiyama K; Nakanishi-Imai M; Ayakawa S; Iida M; Tsuzuki Y; Otsuka S; Manabe Y; Nomura K; Ogawa Y; Miyakawa A; Miyamoto A; Takemoto S; Yasui T; Hiwatashi A
Sci Rep; 2024 Jan; 14(1):113. PubMed ID: 38167430
[TBL] [Abstract][Full Text] [Related]
8. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.
Creak A; Hall E; Horwich A; Eeles R; Khoo V; Huddart R; Parker C; Griffin C; Bidmead M; Warrington J; Dearnaley D
Br J Cancer; 2013 Aug; 109(3):651-7. PubMed ID: 23880826
[TBL] [Abstract][Full Text] [Related]
9. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer.
Gilbert R; Tilling K; Martin RM; Lane JA; Davis M; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
Cancer Causes Control; 2018 Mar; 29(3):383-388. PubMed ID: 29453511
[TBL] [Abstract][Full Text] [Related]
10. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.
Li HZ; Qi X; Gao XS; Li XM; Qin SB; Li XY; Ma MW; Bai Y; Chen JY; Ren XY; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):697-705. PubMed ID: 37717784
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes and late toxicities of intensity-modulated radiation therapy for 1091 Japanese patients with localized prostate cancer.
Tanaka H; Yamaguchi T; Hachiya K; Kamei S; Ishihara S; Hayashi M; Ogawa S; Nishibori H; Goshima S; Matsuo M
Rep Pract Oncol Radiother; 2018; 23(1):28-33. PubMed ID: 29270081
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer.
Samuel E; Zaman S; Bakar MA; Fareed MM
Discov Oncol; 2024 Feb; 15(1):27. PubMed ID: 38305836
[TBL] [Abstract][Full Text] [Related]
13. High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy.
Lischalk JW; Sanchez A; Santos VF; Mendez C; Akerman M; Carpenter T; Tam M; Byun D; Wise DR; Mahadevan A; Evans A; Huang W; Katz A; Lepor H; Haas JA
Radiat Oncol; 2024 Mar; 19(1):29. PubMed ID: 38439040
[TBL] [Abstract][Full Text] [Related]
14. External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
Kuusk T; Pulliainen K; Vaarala MH
Mol Clin Oncol; 2017 Mar; 6(3):428-432. PubMed ID: 28451427
[TBL] [Abstract][Full Text] [Related]
15. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP
Front Oncol; 2023; 13():1289249. PubMed ID: 37916156
[TBL] [Abstract][Full Text] [Related]
16. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials.
Du KL; Bae K; Movsas B; Yan Y; Bryan C; Bruner DW
Support Care Cancer; 2012 Jun; 20(6):1317-25. PubMed ID: 21720747
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
Yamamoto T; Umezawa R; Shimada S; Takahashi N; Takeda K; Suzuki YU; Kishida K; Omata SO; Sato Y; Harada H; Ito A; Jingu K
Anticancer Res; 2023 Nov; 43(11):5115-5125. PubMed ID: 37909950
[TBL] [Abstract][Full Text] [Related]
18. SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.
Bernetich M; Oliai C; Lanciano R; Hanlon A; Lamond J; Arrigo S; Yang J; Good M; Feng J; Brown R; Garber B; Mooreville M; Brady LW
Front Oncol; 2014; 4():312. PubMed ID: 25426447
[TBL] [Abstract][Full Text] [Related]
19. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.
Menne Guricová K; Groen V; Pos F; Monninkhof E; Elias SG; Haustermans K; Smeenk RJ; van der Voort van Zyp J; Draulans C; Isebaert S; van Houdt PJ; Kerkmeijer LGW; van der Heide UA
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):66-73. PubMed ID: 37725026
[TBL] [Abstract][Full Text] [Related]
20. Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database.
Ricco A; Hanlon A; Lanciano R
Front Oncol; 2017; 7():185. PubMed ID: 28913176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
